Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (moderate certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse events (all) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse events (all) (high certainty).
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (high certainty).
1 finding from 1 review
Non‐fatal serious adverse events · children and adolescents with chronic asthma
Regular formoterol and ICS showed no clear difference in all‐cause non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · adults, chronic asthma: all‐cause mortality
Regular formoterol and ICS showed no clear difference in asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (moderate certainty).
1 finding from 1 review
Asthma‐related non‐fatal serious adverse events · children and adolescents with chronic asthma
It is very uncertain whether regular formoterol and ICS changes asthma‐related non‐fatal serious adverse events compared with same‐dose ICS (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events Duration of trials: 12 to 20 weeks · adults and adolescents with persistent asthma
The intervention probably leads to higher serious adverse events Duration of trials: 12 to 20 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review
Patients with serious adverse health events (duration 12 to 52 weeks) · Children and adults with persistent asthma.
Intermittent 'as needed' ICS showed no clear difference in patients with serious adverse health events (duration 12 to 52 weeks) compared with daily ICS (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention leads to higher non‐fatal, serious adverse pneumonia events (requiring hospital… (high certainty).
1 finding from 1 review
Intervention not reported
Non‐fatal, serious adverse pneumonia events (requiring hospital admission) · patients with chronic obstructive pulmonary disease
The intervention showed no clear difference in non‐fatal, serious adverse pneumonia events (requiring hospital… (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events－serious Mometasone/formoterol (MF/F) versus Mometasone (MF) · patients with COPD
The intervention showed no clear difference in adverse events－serious Mometasone/formoterol (MF/F) versus… (low certainty).
1 finding from 1 review
Intervention not reported
Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)
The intervention showed no clear difference in non‐serious adverse eventsClinical manifestation and laboratory… (low certainty).
1 finding from 1 review